Featuring David Gandara, MD and Johannes Kratz, MD
Please visit www.oncocyte.com for more information on DetermaRx
2020 has ushered in two important milestones in early-stage lung cancer. First, CMS approved DetermaRx, a molecular test that identifies patients with Stage I-IIA non-squamous NSCLC who are at high risk of recurrence, and may benefit from adjuvant chemotherapy. Second, the ADAURA trial results, presented at ASCO, demonstrated the efficacy of osimertinib in EGFR-positive early-stage NSCLC. In this webinar, we will review these latest research findings as well as ongoing clinical trials on the use of chemotherapy, targeted therapy, and immunotherapy in early-stage NSCLC. We will also present updated prospective data and clinical adoption trends for DetermaRx.
Key summary points: